Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.30 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10238964 | 0.85 | LMNA (0.39) | PIM1MEN1KMT2APOLBGAA | |
| SCHEMBL10239177 | 0.84 | ALDH1A1 (0.42) | PIM1MEN1KMT2APOLBGAA | |
| SCHEMBL1391156 | 0.83 | USP14 (0.35) | PIM1MEN1KMT2APOLBGAA | |
| SCHEMBL10239175 | 0.80 | MAOB (0.44) | MEN1KMT2APOLBGAAALDH1A1 | |
| SCHEMBL7922463 | 0.72 | NPC1 (0.34) | PIM1MEN1KMT2APOLBGAA | |
| SCHEMBL7674934 | 0.70 | MAOB (0.47) | KMT2AGAAALDH1A1NPC1RAB9A | |
| SCHEMBL1390757 | 0.66 | ALDH1A1 (0.43) | PIM1MEN1KMT2APOLBGAA | |
| SCHEMBL7919465 | 0.66 | ALDH1A1 (0.43) | PIM1MEN1KMT2APOLBGAA | |
| SCHEMBL22549667 | 0.63 | MAOB (0.40) | PIM1MEN1KMT2APOLBGAA | |
| SCHEMBL1390653 | 0.63 | MAOB (0.45) | MEN1KMT2APOLBGAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501804-B2 | Bicyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-08-06 | — | — | US | disclosed |
| US-20120010247-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010247-A1 | BICYCLIC COMPOUND | ACACA, CPT1B, ACACB | PIM1 1965/4885MEN1 2828/4885KMT2A 1599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.